Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Inclusion Criteria: * Recipients of a deceased donor or living donor kidney transplant * Recipients of age greater than 18 years but less than 76 years * African Americans (self-reported patients of Black African descent who live in the United States) * Willingness to participate in a randomized, clinical trial, as indicated by signed informed consent * Patients with a history of gastrointestinal complications including any of the following: a history of diarrhea, constipation, acid reflux, or abdominal pain as reported by the patient * For women of childbearing age, effective contraception must be used before beginning CellCept or Myfortic, during therapy and 6 weeks after therapy has been discontinued (childbearing women should have a negative serum or urine pregnancy test within 1 week prior to starting CellCept or Myfortic therapy) Exclusion Criteria: * Recipients with any prior solid organ transplant (including kidney) * Recipients receiving a concurrent solid organ (heart, liver, pancreas) or cell (islet, bone marrow, stem cell) transplant * Recipient age is less than 18 years old or greater than 75 years old * Recipients who are not African American (self-reported patients of Black African descent who live in the United States) * Recipients on proton pump inhibitor therapy at the time of initial screening (pre-transplant to 2 days post-transplant) * Recipients with a gastrointestinal bleed within the past three months * Recipients who are pregnant or breast feeding …